Managing Severe Respiratory Syncytial Virus


1. Centers for Disease Control and Prevention, Respiratory syncytial virus, 2010. Available at: www.cdc.gov/rsv/ about/infection.html (accessed August 24, 2010 ).


2. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis, Pediatrics, 2006;118:1774–93.


3. 4. 5.


Shay DK, Holman RC, Newman RD, et al., Bronchiolitis-associated hospitalizations among US children, 1980–1996, JAMA, 1999;282:1440–6.


Giles TD, Gohd RS, Respiratory syncytial virus and heart disease. A report of two cases, JAMA, 1976;236:1128–30.


Huang M, Bigos D Levine M, Ventricular arrhythmia associated with respiratory syncytial viral infection, Pediatr Cardiol, 1998;19:498–500.


6. Menahem S, Respiratory syncytial virus and supraventricular tachycardia in an infant, Int J Cardiol, 1991;32:249–51.


7.


Armstrong DS, Menahem S, Cardiac arrhythmias as a manifestation of acquired heart disease in association with paediatric respiratory syncitial virus infection, J Paediatr Child Health, 1993; 29:309–11.


8. Olesch CA, Bullock AM, Bradyarrhythmia and supraventricular tachycardia in a neonate with RSV, J Paediatr Child Health, 1998; 4:199–201.


9. 10. 11. 12. 13. 14.


Donnerstein RL, Berg RA, Shehab Z, et al., Complex atrial tachycardias and respiratory syncytial virus infections in infants, J Pediatr, 1994;125:23–8.


Menahem S, Uren EC, Respiratory syncytial virus and heart block–cause and effect?, Aust N Z J Med, 1985;15:55–7.


Bairan AC, Cherry JD, Fagan LF, et al., Complete heart block and respiratory syncytial virus infection, Am J Dis Child, 1974;127:264–5.


Kristensen K, Stensballe LG, Bjerre J, et al., Risk factors for respiratory syncytial cirus hospitalisation in children with heart disease, Arch Dis Child, 2009;94:785–9.


Checchia PA, Appel HJ, Kahn S, et al., Myocardial injury in children with respiratory syncytial virus infection, Pediatr Crit Care Med, 2000;1:146–50.


Eisenhut M, Sidaras D, Johnson R, et al., Cardiac troponin T levels and myocardial involvement in children with severe respiratory syncytial virus lung disease, Acta Pediatr,


22. 23. 21. 17. 18. 2004;93:887–90. 15.


Moynihan JA, Brown L, Sehra R, et al., Cardiac troponin I as a predictor of respiratory failure in children hospitalized with respiratory syncytial virus (RSV) infections: a pilot study, Am J Emerg Med, 2003;21:479–82.


16.


Dagan R, Hall CB, Powell KR, et al., Epidemiology and laboratory diagnosis of infection with viral and bacterial pathogens in infants hospitalized for suspected sepsis, J Pediatr, 1989;115:351–6.


Njoku DB, Kliegman RM, Atypical extrapulmonary presentations of severe respiratory syncytial virus infection requiring intensive care, Clin Pediatr (Phila), 1993;32:455–60.


Wahab AA, Dawod ST, Raman HM, Clinical characteristics of respiratory syncytial virus infection in hospitalized healthy infants and young children in Qatar, J Trop Pediatr, 2001;47:363–6.


19.


Welliver RC, Checchia PA, Bauman JH, et al., Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children, Curr Med Res Opin, 2010;26:2175–81.


20.


Checchia PA, et al., Reduction in mortality among high-risk preterm infants receiving palivizumab prophylaxis: a systemic review and meta-analysis. Presented at the 2009 Pediatric Academic Societies’ Annual Meeting, May, 2009.


Meissner HC, Welliver RC, Chartrand SA, et al., Immunoprophylaxis with palivizumab, a humanized respiratorysyncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion, Pediatr Infect Dis J, 1999;18:223–31.


Checchia PA, Identification and management of severe RSV infections. Presented at: ASHP Summer Meeting, Seattle, Washington. June 9, 2008.


Weisman LE, Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions, Pediatr Infect Dis J, 2003;22:S33–7.


24. 25.


Boyce TG, Mellen BG, Mitchel EF Jr, et al., Rates of hospitalization for respiratory syncytial virus infection among children in medicaid, J Pediatr, 2000;137:865–70. Langston C, Kida K, Reed M, et al., Human lung growth in


26. 27. 28. 29. 30. 31. 32.


late gestation and in the neonate, Am Rev Respir Dis, 1984;129:607–13.


Yeung CY, Hobbs JR, Serum-gamma-G-globulin levels in normal premature, post-mature, and ‘small-for-dates’ newborn babies, Lancet, 1968;1:1167–70.


Holman RC, Shay DK, Curns AT, et al., Risk factors for bronchiolitis-associated deaths among infants in the United States, Pediatr Infect Dis J, 2003;22:483–90.


Horn SD, Smout RJ, Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes, J Pediatr, 2003;143:S133–41.


Khoshoo V, Edell D, Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis, Pediatrics, 1999;104:1389–90.


Kellner JD, Ohlsson A, Gadomski AM, et al., Bronchodilators for bronchiolitis, Cochrane Database Syst Rev, 2000;CD001266.


Patel H, Platt R, Lozano JM, et al., Glucocorticoids for acute viral bronchiolitis in infants and young children, Cochrane Database Syst Rev, 2004;CD004878.


Roosevelt G, Sheehan K, Grupp-Phelan J, et al., Dexamethasone in bronchiolitis: a randomised controlled trial, Lancet, 1996;348:292–5.


33. American Academy of Pediatrics, Red book: 2006 report of the committee on infectious diseases, 27th ed, Elk Grove, IL: American Academy of Pediatrics, 2006.


34.


Bradley JS, Connor JD, Compogiannis LS, et al., Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections, Antimicrob Agents Chemother, 1990;34:668–70.


35.


Rodriguez WJ, Bui RH, Connor JD, et al., Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections, Antimicrob Agents Chemother, 1987;31:1143–6.


36. 37.


Feldstein TJ, Swegarden JL, Atwood GF, et al., Ribavirin therapy: implementation of hospital guidelines and effect on usage and cost of therapy, Pediatrics, 1995;96:14–7.


Friis B, Andersen P, Brenoe E, et al., Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study, Arch Dis Child, 1984;59:1038–45.


US RESPIRATORY DISEASE


59


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84